[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1055899A1 - Vaccine composition comprising an antigen and a peptide having adjuvant properties - Google Patents

Vaccine composition comprising an antigen and a peptide having adjuvant properties

Info

Publication number
HK1055899A1
HK1055899A1 HK03108189A HK03108189A HK1055899A1 HK 1055899 A1 HK1055899 A1 HK 1055899A1 HK 03108189 A HK03108189 A HK 03108189A HK 03108189 A HK03108189 A HK 03108189A HK 1055899 A1 HK1055899 A1 HK 1055899A1
Authority
HK
Hong Kong
Prior art keywords
peptide
antigen
amino acid
acid residue
vaccine composition
Prior art date
Application number
HK03108189A
Other languages
English (en)
Inventor
Joerg Fritz
Frank Mattner
Wolfgang Zauner
Eszter Nagy
Michael Buschle
Original Assignee
Intercell Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Ag filed Critical Intercell Ag
Publication of HK1055899A1 publication Critical patent/HK1055899A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK03108189A 2000-10-18 2003-11-12 Vaccine composition comprising an antigen and a peptide having adjuvant properties HK1055899A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0178900A AT410635B (de) 2000-10-18 2000-10-18 Vakzin-zusammensetzung
PCT/EP2001/012041 WO2002032451A1 (en) 2000-10-18 2001-10-18 Vaccine composition comprising an antigen and a peptide having adjuvant properties

Publications (1)

Publication Number Publication Date
HK1055899A1 true HK1055899A1 (en) 2004-01-30

Family

ID=3688953

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03108189A HK1055899A1 (en) 2000-10-18 2003-11-12 Vaccine composition comprising an antigen and a peptide having adjuvant properties

Country Status (27)

Country Link
US (3) US8361476B2 (xx)
EP (1) EP1326634B1 (xx)
JP (2) JP4227407B2 (xx)
KR (1) KR100598302B1 (xx)
CN (1) CN1248736C (xx)
AT (2) AT410635B (xx)
AU (2) AU1232602A (xx)
BR (1) BRPI0114994B8 (xx)
CA (1) CA2426490C (xx)
CZ (1) CZ303303B6 (xx)
DE (1) DE60119145T2 (xx)
DK (1) DK1326634T3 (xx)
ES (1) ES2263668T3 (xx)
HK (1) HK1055899A1 (xx)
HU (1) HU228382B1 (xx)
IL (2) IL154605A0 (xx)
IS (1) IS2608B (xx)
MX (1) MXPA03002828A (xx)
NO (1) NO330274B1 (xx)
NZ (1) NZ524532A (xx)
PL (1) PL209016B1 (xx)
PT (1) PT1326634E (xx)
RU (2) RU2328305C2 (xx)
SI (1) SI1326634T1 (xx)
SK (1) SK287618B6 (xx)
WO (1) WO2002032451A1 (xx)
ZA (1) ZA200301465B (xx)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410635B (de) * 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
JP2004519452A (ja) * 2001-01-05 2004-07-02 インターツェル・アクチェンゲゼルシャフト ポリカチオン性化合物の用途
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP1279404A1 (en) 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA2484941A1 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
CA2484339A1 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
EP2314603A3 (en) 2002-10-15 2011-05-18 Intercell AG Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and futher uses thereof
EP2287315A1 (en) 2003-03-04 2011-02-23 Intercell AG Streptococcus pyogenes antigens
CA2517673C (en) 2003-03-24 2013-08-13 Intercell Ag Improved vaccines for preventing viral infection
CN101214375B (zh) * 2003-03-24 2011-04-06 英特塞尔股份公司 改进的疫苗
US7628994B2 (en) 2003-03-31 2009-12-08 Intercell Ag S. epidermidis antigens
US7635487B2 (en) 2003-04-15 2009-12-22 Intercell Ag S. pneumoniae antigens
US8076059B2 (en) * 2003-04-16 2011-12-13 Duke University Adjuvant capable of specifically activating the adaptive immune response
JP2007535894A (ja) 2003-05-07 2007-12-13 インターツェル・アクチェンゲゼルシャフト ストレプトコッカス・アガラクティエ抗原ｉ＋ｉｉ
CA2525540A1 (en) 2003-05-30 2004-12-09 Intercell Ag Enterococcus antigens
JP4734241B2 (ja) * 2003-07-11 2011-07-27 インターツェル・アクチェンゲゼルシャフト Ｈｃｖワクチン
EP1987843A3 (en) 2004-03-12 2011-10-26 Intercell AG Method for solubilising peptide mixtures
EP1791858B1 (en) 2004-09-24 2010-04-21 Intercell AG Modified vp1-capsid protein of parvovirus b19
EP2471550A1 (en) 2005-10-07 2012-07-04 Health Protection Agency Proteins with improved solubility and methods for producing and using same
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
KR20090024292A (ko) 2006-06-28 2009-03-06 스태튼스 세룸 인스티튜트 단백질 단편 또는 펩타이드 혼합물로서 전달되는 항원을 가진 백신접종에 의해 준우성 항원결정기를 포함하는 ｔ세포 레퍼토리 확장
EP2059531A1 (en) 2006-07-07 2009-05-20 Intercell AG Small streptococcus pyogenes antigens and their use
WO2008031133A2 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
EP1923069A1 (en) 2006-11-20 2008-05-21 Intercell AG Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2120984A2 (en) 2007-01-12 2009-11-25 Intercell AG Protective proteins of s. agalactiae, combinations thereof and methods of using the same
JP2010532657A (ja) 2007-05-02 2010-10-14 インターセル アーゲー クレブシエラ属の抗原
EP2012122A1 (en) 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
WO2008145400A2 (en) 2007-05-31 2008-12-04 Medigene Ag Mutated structural protein of a parvovirus
WO2008155291A2 (en) 2007-06-18 2008-12-24 Intercell Ag Chlamydia antigens
JP2011514167A (ja) 2008-03-17 2011-05-06 インターセル アーゲー 肺炎連鎖球菌（Ｓ．ｐｎｅｕｍｏｎｉａｅ）に対して保護的なペプチドならびにそれに関連する組成物、方法、および使用
CN101980721B (zh) 2008-04-02 2013-03-13 国立大学法人德岛大学 含有合成肽的抗原药物赋形剂和使用其的粘膜疫苗
RU2010151562A (ru) 2008-06-20 2012-07-27 ВАЙЕТ ЭлЭлСи (US) Композиции и способы применения orf1358 из бета-гемолитических стрептококковых штаммов
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
EP2424882A2 (en) 2009-02-05 2012-03-07 Intercell AG Peptides protective against e. faecalis, methods and uses relating thereto
EP2405938A2 (en) 2009-02-13 2012-01-18 Intercell AG Nontypable haemophilus influenzae antigens
CN102625713A (zh) 2009-06-22 2012-08-01 惠氏有限责任公司 用于制备金黄色葡萄球菌血清型5和8荚膜多糖缀合物免疫原性组合物的组合物和方法
NZ597154A (en) 2009-06-22 2013-10-25 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
NZ598459A (en) 2009-08-27 2014-03-28 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
EP2308896A1 (en) 2009-10-09 2011-04-13 Sanofi-aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
EP2319871A1 (en) 2009-11-05 2011-05-11 Sanofi-aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
KR20120089863A (ko) 2009-10-09 2012-08-14 사노피 “개선된 당화반응 최종 생성물에 대한 수용체”에 결합하기 위한 폴리펩타이드 및 이를 포함하는 조성물 및 방법
WO2011101465A1 (en) 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
EP2547357A1 (en) 2010-03-18 2013-01-23 Novartis AG Adjuvanted vaccines for serogroup b meningococcus
PL3170508T3 (pl) 2010-06-04 2020-04-30 Wyeth Llc Preparaty szczepionek
PL3246044T5 (pl) 2010-08-23 2024-06-17 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
PL2753352T5 (pl) 2010-09-03 2022-10-17 Valneva Austria Gmbh Izolowany polipeptyd białek toksyny a i toksyny b z c. difficile i jego zastosowania
AR082925A1 (es) 2010-09-08 2013-01-16 Medigene Ag Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados
ES2728282T3 (es) 2010-09-10 2019-10-23 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
DK2654784T3 (en) 2010-12-22 2017-02-13 Wyeth Llc STABLE IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENES
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
RU2665841C2 (ru) 2012-03-09 2018-09-04 Пфайзер Инк. Композиции neisseria meningitidis и способы их применения
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN104428411B (zh) * 2012-05-08 2018-11-23 健康科学西部大学 用于cd4+t细胞群之抗原特异性扩增的标准化离体平台
CN109364244B (zh) * 2012-10-29 2022-04-29 阿肯色大学评议会 黏膜佐剂和递送系统
DK3363806T3 (da) 2012-12-20 2022-11-21 Pfizer Glycokonjugationsfremgangsmåde
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
US20140271723A1 (en) * 2013-03-15 2014-09-18 Saint Louis University Adjuvant compositions and methods of using thereof
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
WO2016130569A1 (en) 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
SG11201708242YA (en) 2015-05-04 2017-11-29 Pfizer Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
CN113521007B (zh) * 2016-07-01 2022-11-18 四川大学 抗菌肽衍生物在制备免疫佐剂中的用途
US10751402B2 (en) 2016-11-09 2020-08-25 Pfizer Inc. Immunogenic compositions and uses thereof
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
CN107266585B (zh) * 2017-07-13 2019-08-06 陕西科技大学 一种mlh融合抗菌肽及其制备方法和应用
EP3527223A1 (en) 2018-02-16 2019-08-21 2A Pharma AB Mutated parvovirus structural protein
EP3752184A1 (en) 2018-02-16 2020-12-23 2A Pharma AB Parvovirus structural protein for the treatment of autoimmune diseases
CN109745556A (zh) * 2019-03-01 2019-05-14 龙阔（苏州）生物工程有限公司 一种疫苗佐剂及其应用及猪繁殖与呼吸综合征疫苗
CN114127101A (zh) 2019-05-20 2022-03-01 瓦尔尼瓦公司 用于治疗或预防呼吸道感染的亚单位疫苗
WO2021202456A1 (en) * 2020-03-30 2021-10-07 The Wistar Institute Of Anatomy And Biology Synthetic soluble receptor mimics and methods of use for treatment of covid-19
WO2021211279A1 (en) 2020-04-17 2021-10-21 Regents Of The University Of Minnesota SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF
KR20230056727A (ko) 2020-08-26 2023-04-27 화이자 인코포레이티드 B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도
MX2023010370A (es) 2021-04-09 2023-09-12 Valneva Se Vacuna del metapneumovirus humano.
WO2023083964A1 (en) 2021-11-11 2023-05-19 2A Pharma Ab Parvovirus structural protein against beta- and gamma-hpv
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721341A4 (en) * 1993-08-06 1998-04-22 Cytel Corp CLONING AND DESCRIPTION OF FULL MAGE-1 GENE CHARACTERISTICS
JP3442824B2 (ja) * 1993-08-30 2003-09-02 理化学研究所 抗菌性ペプチド類
JP3547504B2 (ja) * 1994-11-01 2004-07-28 独立行政法人理化学研究所 新規なポリペプチド及びその用途
EP0991767A1 (en) * 1997-06-11 2000-04-12 Institut Pasteur Attenuated recombinant mycobacteria useful as immunogens or as vaccine components
ES2248914T3 (es) * 1997-08-29 2006-03-16 Corixa Corporation Agentes bioactivos encapsulados de liberacion rapida que permiten inducir o potenciar una respuesta inmunitaria y metodos para utilizar los mismos.
CU22700A1 (es) * 1997-09-29 2001-07-31 Ct Ingenieria Genetica Biotech Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso
US20020072495A1 (en) * 2000-09-21 2002-06-13 Oleg Chertov LL-37 is an immunostimulant
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
CN101214375B (zh) * 2003-03-24 2011-04-06 英特塞尔股份公司 改进的疫苗
CA2517673C (en) 2003-03-24 2013-08-13 Intercell Ag Improved vaccines for preventing viral infection
JP4734241B2 (ja) * 2003-07-11 2011-07-27 インターツェル・アクチェンゲゼルシャフト Ｈｃｖワクチン

Also Published As

Publication number Publication date
AU1232602A (en) 2002-04-29
ES2263668T3 (es) 2006-12-16
CN1248736C (zh) 2006-04-05
CZ20031299A3 (cs) 2003-10-15
US8900564B2 (en) 2014-12-02
CZ303303B6 (cs) 2012-07-25
JP2008222721A (ja) 2008-09-25
BRPI0114994B8 (pt) 2021-05-25
EP1326634B1 (en) 2006-04-26
JP2004511528A (ja) 2004-04-15
HUP0302117A3 (en) 2004-11-29
DE60119145D1 (de) 2006-06-01
SK5752003A3 (en) 2003-12-02
NO20031595L (no) 2003-06-05
DK1326634T3 (da) 2006-08-14
PL362966A1 (en) 2004-11-02
IL154605A (en) 2009-05-04
NZ524532A (en) 2004-10-29
PL209016B1 (pl) 2011-07-29
MXPA03002828A (es) 2003-07-14
US8361476B2 (en) 2013-01-29
DE60119145T2 (de) 2007-02-01
PT1326634E (pt) 2006-09-29
ATE324116T1 (de) 2006-05-15
AU2002212326B2 (en) 2006-01-05
NO20031595D0 (no) 2003-04-08
KR100598302B1 (ko) 2006-07-07
IS2608B (is) 2010-04-15
CA2426490A1 (en) 2002-04-25
US20090123486A1 (en) 2009-05-14
RU2328305C2 (ru) 2008-07-10
IL154605A0 (en) 2003-09-17
ATA17892000A (de) 2002-11-15
HUP0302117A2 (hu) 2003-09-29
BRPI0114994B1 (pt) 2017-11-07
IS6722A (is) 2003-02-20
NO330274B1 (no) 2011-03-14
AT410635B (de) 2003-06-25
WO2002032451A1 (en) 2002-04-25
RU2007146372A (ru) 2009-06-20
US20130216583A1 (en) 2013-08-22
CA2426490C (en) 2012-01-31
ZA200301465B (en) 2004-02-24
US20050063978A1 (en) 2005-03-24
HU228382B1 (en) 2013-03-28
EP1326634A1 (en) 2003-07-16
CN1468109A (zh) 2004-01-14
WO2002032451A8 (en) 2002-05-23
BR0114994A (pt) 2003-09-30
JP4227407B2 (ja) 2009-02-18
KR20030043993A (ko) 2003-06-02
SK287618B6 (sk) 2011-04-05
SI1326634T1 (sl) 2006-10-31

Similar Documents

Publication Publication Date Title
HK1055899A1 (en) Vaccine composition comprising an antigen and a peptide having adjuvant properties
PL324531A1 (en) Derivatives of cyclosporin effective against hiv virus
RU2003114434A (ru) Вакцинная композиция
HK1036804A1 (en) Peptide composition as immunogen for the treatment of allergy
AU5717301A (en) Apo-ai/aii peptide derivatives
DE60127113D1 (de) Gd3 mimetische peptide
WO2003090667A3 (fr) Composition immunogene ou vaccinale non immunosuppressive, comprenant une proteine e7 mutee du virus hpv-16
MXPA02012664A (es) Peptidos para la preparacion de vacunas contra bordetella pertussis y bordetella parapertussis.
NZ508812A (en) Peptides for the prevention or treatment of HIV
WO1994004565A3 (en) Ipnv vaccine
WO2001074847A3 (en) T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
DE69827880D1 (de) Iga1-protease fragment als trägerpeptid
EP0290246A3 (en) Vaccine for generating an immunogenic t cell response protective against rabies virus
DE60124299D1 (de) Peptide aus dem b-glycoprotein des menschlichen herpesvirus-7, besonders anwendbar bei serologischen elisa-nachweisen
EP0959895A4 (en) PEPTIDES SENSITIVE TO ANTIBODIES DIRECTED AGAINST A CONSENSUS PEPTIDE OF PROTEINS OF THE C54-CFA / I FAMILY
SE0002738D0 (sv) Electric actuator
SE0002728D0 (sv) New compound

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20211017